RUNX1 methylation as a cancer biomarker in differentiating papillary thyroid cancer from benign thyroid nodules

Papers of special note have been highlighted as: •• of considerable interest

References

• 1. Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. Lancet 388(10061), 2783–2795 (2016). •• This authoritative and well-known article focuses on the incidence and mortality of thyroid cancer worldwide and describes in detail the clinical characteristics, molecular diagnosis and treatment of different subtypes.
  Medline CASGoogle Scholar
• 2. Solis-Pazmino P, Salazar-Vega J, Lincango-Naranjo E et al. Thyroid cancer overdiagnosis and overtreatment: a cross-sectional study at a thyroid cancer referral center in Ecuador. BMC Cancer 21(1), 42 (2021).
  Medline CASGoogle Scholar
• 3. Roman BR, Morris LG, Davies L. The thyroid cancer epidemic, 2017 perspective. Curr. Opin. Endocrinol. Diabetes Obes. 24(5), 332–336 (2017).
  MedlineGoogle Scholar
• 4. Kitahara CM, Sosa JA. The changing incidence of thyroid cancer. Nat. Rev. Endocrinol. 12(11), 646–653 (2016).
  MedlineGoogle Scholar
• 5. Kim J, Gosnell JE, Roman SA. Geographic influences in the global rise of thyroid cancer. Nat. Rev. Endocrinol. 16(1), 17–29 (2020).
  MedlineGoogle Scholar
• 6. Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin. Med. J. (Engl.) 134(7), 783–791 (2021).
  MedlineGoogle Scholar
• 7. Todsen T, Bennedbaek FN, Kiss K, Hegedus L. Ultrasound-guided fine-needle aspiration biopsy of thyroid nodules. Head Neck 43(3), 1009–1013 (2021). •• This paper highlights the importance of fine needle aspiration biopsy in assessing the characteristics of thyroid nodules and points out that the accuracy of fine needle aspiration biopsy is highly dependent on the proficiency and expertise of the operators and specialist physicians.
  MedlineGoogle Scholar
• 8. Cibas ES, Ali SZ. The Bethesda system for reporting thyroid cytopathology. Thyroid 19(11), 1159–1165 (2009).
  MedlineGoogle Scholar
• 9. Wong LQ, Baloch ZW. Analysis of the Bethesda system for reporting thyroid cytopathology and similar precursor thyroid cytopathology reporting schemes. Adv. Anat. Pathol. 19(5), 313–319 (2012).
  MedlineGoogle Scholar
• 10. Godazandeh G, Kashi Z, Zargarnataj S et al. Evaluation the relationship between thyroid nodule size with malignancy and accuracy of fine needle aspiration biopsy (FNAB). Acta Inform. Med. 24(5), 347–350 (2016).
  MedlineGoogle Scholar
• 11. Cap J, Ryska A, Rehorkova P et al. Sensitivity and specificity of the fine needle aspiration biopsy of the thyroid: clinical point of view. Clin. Endocrinol. (Oxf.) 51(4), 509–515 (1999).
  Medline CASGoogle Scholar
• 12. Jiang C, Gu J. History and current state of pathology in China. Virchows Arch. 463(4), 599–608 (2013).
  MedlineGoogle Scholar
• 13. Provenzano E, Driskell OJ, O'Connor DJ et al. The important role of the histopathologist in clinical trials: challenges and approaches to tackle them. Histopathology 76(7), 942–949 (2020).
  MedlineGoogle Scholar
• 14. Livhits MJ, Zhu CY, Kuo EJ et al. Effectiveness of molecular testing techniques for diagnosis of indeterminate thyroid nodules: a randomized clinical trial. JAMA Oncol. 7(1), 70–77 (2021).
  MedlineGoogle Scholar
• 15. Hu MI, Waguespack SG, Dosiou C et al. Afirma genomic sequencing classifier and xpression atlas molecular findings in consecutive Bethesda III–VI thyroid nodules. J. Clin. Endocrinol. Metab. 106(8), 2198–2207 (2021).
  MedlineGoogle Scholar
• 16. Klutstein M, Nejman D, Greenfield R, Cedar H. DNA methylation in cancer and aging. Cancer Res. 76(12), 3446–3450 (2016).
  Medline CASGoogle Scholar
• 17. Zafon C, Gil J, Perez-Gonzalez B, Jorda M. DNA methylation in thyroid cancer. Endocr. Relat. Cancer 26(7), R415–R439 (2019). •• This paper comprehensively investigates the potential clinical application value of DNA methylation as a biomarker in the diagnosis, treatment and prognosis of thyroid cancer.
  Medline CASGoogle Scholar
• 18. Hoffman RM. Altered methionine metabolism, DNA methylation and oncogene expression in carcinogenesis. A review and synthesis. Biochim. Biophys. Acta 738(1–2), 49–87 (1984).
  Medline CASGoogle Scholar
• 19. Ragoussis J, Elvidge GP, Kaur K, Colella S. Matrix-assisted laser desorption/ionisation, time-of-flight mass spectrometry in genomics research. PLoS Genet. 2(7), e100 (2006).
  MedlineGoogle Scholar
• 20. Koziolek M, Binczak-Kuleta A, Stepaniuk M et al. Frequency assessment of BRAF mutation, KRas mutation, and RASSF1A methylation in nodular goitre based on fine-needle aspiration cytology specimens Ocena czestosci wystepowania mutacji genow BRAF, KRas oraz. Endokrynol. Pol. 66(5), 384–393 (2015).
  Medline CASGoogle Scholar
• 21. Khatami F, Larijani B, Heshmat R et al. Hypermethylated RASSF1 and SLC5A8 promoters alongside BRAF(V600E) mutation as biomarkers for papillary thyroid carcinoma. J. Cell. Physiol. 235(10), 6954–6968 (2020).
  Medline CASGoogle Scholar
• 22. Lamartina L, Grani G, Arvat E et al. 8th edition of the AJCC/TNM staging system of thyroid cancer: what to expect (ITCO#2). Endocr. Relat. Cancer 25(3), L7–L11 (2018).
  MedlineGoogle Scholar
• 23. Yang R, Stocker S, Schott S et al. The association between breast cancer and S100P methylation in peripheral blood by multicenter case–control studies. Carcinogenesis 38(3), 312–320 (2017).
  Medline CASGoogle Scholar
• 24. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25(4), 402–408 (2001).
  Medline CASGoogle Scholar
• 25. Rodriguez-Rodero S, Delgado-Alvarez E, Fernandez AF et al. Epigenetic alterations in endocrine-related cancer. Endocr. Relat. Cancer 21(4), R319–R330 (2014).
  Medline CASGoogle Scholar
• 26. Barros-Filho MC, Dos Reis MB, Beltrami CM et al. DNA methylation-based method to differentiate malignant from benign thyroid lesions. Thyroid 29(9), 1244–1254 (2019).
  Medline CASGoogle Scholar
• 27. Mevel R, Draper JE, Lie ALM, Kouskoff V, Lacaud G. RUNX transcription factors: orchestrators of development. Development 146(17), dev148296 (2019).
  MedlineGoogle Scholar
• 28. Sood R, Kamikubo Y, Liu P. Role of RUNX1 in hematological malignancies. Blood 129(15), 2070–2082 (2017).
  Medline CASGoogle Scholar
• 29. Wang L, Huang G, Zhao X et al. Post-translational modifications of Runx1 regulate its activity in the cell. Blood Cells Mol. Dis. 43(1), 30–34 (2009).
  Medline CASGoogle Scholar
• 30. Liu C, Xu D, Xue B et al. Upregulation of RUNX1 suppresses proliferation and migration through repressing VEGFA expression in hepatocellular carcinoma. Pathol. Oncol. Res. 26(2), 1301–1311 (2020).
  Medline CASGoogle Scholar
• 31. Zhuang M, Gao W, Xu J, Wang P, Shu Y. The long non-coding RNA H19-derived miR-675 modulates human gastric cancer cell proliferation by targeting tumor suppressor RUNX1. Biochem. Biophys. Res. Commun. 448(3), 315–322 (2014).
  Medline CASGoogle Scholar
• 32. Kim Y, Lee BB, Kim D et al. Clinicopathological significance of RUNX1 in non-small cell lung cancer. J. Clin. Med. 9(6), 1694 (2020).
  Medline CASGoogle Scholar
• 33. Planaguma J, Gonzalez M, Doll A et al. The up-regulation profiles of p21WAF1/CIP1 and RUNX1/AML1 correlate with myometrial infiltration in endometrioid endometrial carcinoma. Hum. Pathol. 37(8), 1050–1057 (2006).
  Medline CASGoogle Scholar
• 34. Tang CY, Wu M, Zhao D et al. Runx1 is a central regulator of osteogenesis for bone homeostasis by orchestrating BMP and WNT signaling pathways. PLoS Genet. 17(1), e1009233 (2021).
  Medline CASGoogle Scholar
• 35. Xu J, Zheng G, Guo H et al. Bioinformatics analysis of downstream circRNAs and miRNAs regulated by runt-related transcription factor 1 in papillary thyroid carcinoma. Gland Surg. 11(5), 868–881 (2022).
  Medline CASGoogle Scholar
• 36. Chu J, Tao L, Yao T et al. Circular RNA circRUNX1 promotes papillary thyroid cancer progression and metastasis by sponging miR-296-3p and regulating DDHD2 expression. Cell Death Dis. 12(1), 112 (2021).
  Medline CASGoogle Scholar
• 37. Zitti B, Hoffer E, Zheng W et al. Human skin-resident CD8(+) T cells require RUNX2 and RUNX3 for induction of cytotoxicity and expression of the integrin CD49a. Immunity 56(6), 1285–1302 e1287 (2023).
  Medline CASGoogle Scholar
• 38. Matsumura T, Nakamura-Ishizu A, Muddineni S et al. Hematopoietic stem cells acquire survival advantage by loss of RUNX1 methylation identified in familial leukemia. Blood 136(17), 1919–1932 (2020).
  MedlineGoogle Scholar
• 39. Gao L, Zhou F. Comprehensive analysis of RUNX and TGF-beta mediated regulation of immune cell infiltration in breast cancer. Front. Cell Dev. Biol. 9, 730380 (2021).
  MedlineGoogle Scholar
• 40. Papanicolau-Sengos A, Aldape K. DNA methylation profiling: an emerging paradigm for cancer diagnosis. Annu. Rev. Pathol. 17, 295–321 (2022).
  Medline CASGoogle Scholar
• 41. Saghafinia S, Mina M, Riggi N, Hanahan D, Ciriello G. Pan-cancer landscape of aberrant DNA methylation across human tumors. Cell Rep. 25(4), 1066–1080 e1068 (2018).
  Medline CASGoogle Scholar
• 42. Han R, Sun W, Huang J, Shao L, Zhang H. Sex-biased DNA methylation in papillary thyroid cancer. Biomark. Med. 15(2), 109–120 (2021).
  CASGoogle Scholar
• 43. Boks MP, Derks EM, Weisenberger DJ et al. The relationship of DNA methylation with age, gender and genotype in twins and healthy controls. PLOS ONE 4(8), e6767 (2009).
  MedlineGoogle Scholar
• 44. Zeng H, Chen W, Zheng R et al. Changing cancer survival in China during 2003–15: a pooled analysis of 17 population-based cancer registries. Lancet Glob. Health 6(5), e555–e567 (2018).
  MedlineGoogle Scholar
• 45. La Vecchia C, Malvezzi M, Bosetti C et al. Thyroid cancer mortality and incidence: a global overview. Int. J. Cancer 136(9), 2187–2195 (2015).
  MedlineGoogle Scholar
• 46. Kondakova EV, Vershinina OS, Lopatenko MV et al. Sex-specific age-related changes in methylation of certain genes. Sovrem. Tekhnologii Med. 13(3), 26–31 (2021).
  Medline CASGoogle Scholar
• 47. Ulisse S, Baldini E, Lauro A et al. Papillary thyroid cancer prognosis: an evolving field. Cancers (Basel) 13(21), 5567 (2021).
  Medline CASGoogle Scholar
• 48. Shaha AR. TNM classification of thyroid carcinoma. World J. Surg. 31(5), 879–887 (2007).
  MedlineGoogle Scholar
• 49. Xu H, Zhang Y, Wu H et al. High diagnostic accuracy of epigenetic imprinting biomarkers in thyroid nodules. J. Clin. Oncol. 41(6), 1296–1306 (2023).
  Medline CASGoogle Scholar
• 50. Ruiz EML, Niu T, Zerfaoui M et al. A novel gene panel for prediction of lymph-node metastasis and recurrence in patients with thyroid cancer. Surgery 167(1), 73–79 (2020).
  MedlineGoogle Scholar
• 51. Ying T, Wang X, Yao Y et al. Integrative methylome and transcriptome characterization identifies SERINC2 as a tumor-driven gene for papillary thyroid carcinoma. Cancers (Basel) 15(1), 243 (2022).
  MedlineGoogle Scholar
• 52. Krajewska J, Kukulska A, Oczko-Wojciechowska M et al. Early diagnosis of low-risk papillary thyroid cancer results rather in overtreatment than a better survival. Front. Endocrinol. (Lausanne) 11, 571421 (2020).
  MedlineGoogle Scholar